Akademik Veri Yönetim Sistemi
TBD Uluslararası Laboratuvar Tıbbı Zirvesi, Erzurum, Türkiye, 28 - 31 Ekim 2025, ss.25-30, (Tam Metin Bildiri)
Abstract
Objective: COVID-19 is
an acute respiratory disease caused by the SARS-CoV-2 virus. Vaccination is the
most effective and economical way to prevent the disease. In this study, the
immune response in individuals who received two different COVID-19 vaccines (BioNTech
and CoronaVac) was measured to determine changes in antibody levels over time.
Methods: A total of
67 individuals who received two doses of Covid-19 vaccine (BioNTech: n=42,
CoronaVac: n=25) were included in the study. Blood samples were collected from
all volunteers three times: before vaccination, 14 days after the first dose,
and 14 days after the second dose. Serum immunoglobulin G (IgG) and
immunoglobulin M (IgM) levels in the samples were measured quantitatively using
the ELISA method. IgM and IgG levels were measured at baseline (IgG0, IgM0),
after the first vaccine (IgG1, IgM1), and after the second vaccine (IgG2,
IgM2), and changes in antibody levels over time were evaluated. The difference
in IgG and IgM levels created by each vaccine was evaluated using the Tukey
test following a one-way ANOVA test.
Results: After the
second dose of vaccination, serum IgG levels in individuals who received the
CoronaVac and BioNTech vaccines increased significantly compared to baseline.
IgM levels remained unchanged after two doses in individuals who received
CoronaVac, while they decreased significantly after the first and second doses
in individuals who received BioNTech compared to baseline (p=0.009).
Conclusion: Two doses of
vaccine are necessary for a strong and lasting antibody response. BioNTech
vaccine induces higher IgG levels. Completing both doses of vaccines during
epidemics is important for controlling epidemics and achieving herd immunity.
Keywords: Antibody, Covid-19,
IgG, IgM